LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive.All ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Dealmaking is in style again under President Donald Trump. Potential takeover targets include C3.ai, Viking Therapeutics, and ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...